close icon

Search

News

INBIOTECH participated in The XVI National Congress of Cardiology in Albena Resort
10 October, 2018

INBIOTECH participated in The XVI National Congress of Cardiology in Albena Resort

INBIOTECH presented medicinal products under medical prescription, as well as nutraceutical products in the cardiological therapeutic area at the XVI National Congress of Cardiology. The event was held on 4-7 October, 2018 at Albena Resort. The Congress was organized by the Bulgarian Society of Cardiology

At the Forum we presented our medicinal products under medical prescription:

CORLEDIN® 7,5 mg

Indicated for treatment of chronic stable angina pectoris, as well as for chronic heart failure. 

Telsol Plus® 80 mg / 12.5 mg & Telsol Plus® 80 mg / 25 mg

Indicated for treatment of essential hypertension. 

Valsol Plus® 160 mg / 25 mg

Indicated for treatment of essential hypertension.

ENPRIL® 5 mg, ENPRIL® 10 mg & ENPRIL® 20 mg

Indicated for treatment of essenatial hypertension and heart failure. 

We also presented our food supplement LIPONORM® 2 g

This nutraceutical product is indicated for beneficial effect on the lipid balance and metabolism. LIPONORM® acts beneficially on the functions of the heart and the digestive system. The food supplement possesses favourable effect on arterial pressure and functions of the liver.


Thank you!

We would like to thank all participating cardiologists who visited our stand. Thank you also for your interest in our Rx medicinal products and nutraceutical products in the cardiological therapeutic area. In case of any questions, related to any of these products, please contact us and we will be happy to respond to them. 

We would also like to thank the Bulgarian Society of Cardiologists for their support throughout all these years. We will continue to collaborate effectively, in order to achieve our mutual goal of improving the lives of patients with cardiological problems in Bulgaria. INBIOTECH will strive to participate in as many events, organized by BSC, in order to reach directly as many cardiologists as possible.

 

 

 

Back to all news